MedTrace Logo

Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism

NCT01081665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 237

Last updated 2012-03-27

Study results available
· View outcomes & findings →

Summary

The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product Characteristics for the treatment of secondary hyperparathyroidism in hemodialysis patients in Greece.

Conditions

  • Chronic Kidney Failure
  • Secondary Hyperparathyroidism

Sponsors & Collaborators

Principal Investigators

  • Konstantinos Xynos, MD · Abbott Laboratories Hellas S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Greece

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01081665 on ClinicalTrials.gov